Drug intelligence / Profile preview

orlistat + chromium picolinate

Development stage
Unknown
Lead developer
Penta Pharma
Modality
Small Molecules
Administration
Oral
01

Overview

Regigreen Plus is an oral weight management medication developed by Penta Pharma. It is a combination product containing orlistat, a potent gastric and pancreatic lipase inhibitor, and chromium picolinate, a trace mineral used to support glucose metabolism. Orlistat works locally in the gastrointestinal tract by forming a covalent bond with the active serine site of lipases, preventing the hydrolysis of dietary fats (triglycerides) into absorbable free fatty acids and monoglycerides. This results in approximately 30% of ingested fat passing through the intestines unabsorbed. Chromium picolinate is included to potentially enhance insulin sensitivity and assist in appetite regulation. The product is indicated for the treatment of obesity and weight maintenance in conjunction with a reduced-calorie diet.

Brand names
Regigreen Plus
02

Targets

INSR (Insulin receptor)LIPF (Gastric lipase)PNLIP (Pancreatic triacylglycerol lipase)

Beyond the preview

Go deeper on orlistat + chromium picolinate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on orlistat + chromium picolinate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call